August 2nd, 2021


Volume 57
Number 4
   
 Editorial
277


 Symposium
 Gestational Trophoblastic Disease: Presentations from the XVIth World Congress on Gestational Trophoblastic Diseases
279
S. Killick, M.D., J. Cook, RGN, S. Gillett, RGN, L. Ellis, B.Sc., J. Tidy, M.D., and B. W. Hancockm, M.D.
Diagnosis of gestational trophoblastic disease is being made earlier. More patients developing gestational trophoblastic neoplasia are receiving chemotherapy as opposed to second uterine evacuation.


283
J. R. Lurain, M.D., E. Chapman-Davis, M.D., A. V. Hoekstra M.D., M.P.H., and J. C. Schink, M.D.
Actinomycin D used as secondary therapy in methotrexate-failed low-risk gestational trophoblastic neoplasia resulted in a 75% complete response rate and eventual 100% cure with subsequent multiagent chemotherapy with or without surgery.


288
N. L. Neubauer, M.D., N. Latif, M.D., K. Kalakota, M.D., M. Marymont, M.D., W. Small, Jr., M.D., J. C. Schink, M.D., and J. R. Lurain, M.D.
The majority of patients with metastatic gestational trophoblastic neoplasia to the brain can be cured with a combination of systemic multiagent chemotherapy and whole brain irradiation.


293
S. J. Kingdon, B.Med.Sci., R. E. Coleman, M.D., L. Ellis, B.Sc., and B. W. Hancock, M.D.
Death may still occur with multidrug-resistant placental site trophoblastic tumor and choriocarcinoma. New strategies are needed to manage these patients.


297
A. Hassadia, M.D., F. M. Kew, M.D., J. A. Tidy, M.D., M. Wells, M.D., and B. W. Hancock, M.D.
Ectopic GTD is rare and still overdiagnosed. Expert histology review is indicated, especially where there is clinical or histopathologic concern.


301
Y. Sasaki, M.D., Ph.D., K. Ogawa, M.D., Ph.D., J. Takahashi, M.D., Ph.D., and T. Okai, M.D., Ph.D.
It is possible to achieve a healthy newborn in cases of complete mole and coexisting fetus, though the management may be complicated by the development of subsequent gestational trophoblastic neoplasia.


305
P. R. Sobral Dantas, M.D., I. Maestá, M.D., R. Cortés-Charry, M.D., W. B. Growdon, M.D., A. Braga, M.D., M. V. Cunha Rudge, M.D., and R. S. Berkowitz, M.D.
This study underscores the fact that follow-up of hydatidiform mole in specialist centers improves gestational trophoblastic neoplasia outcome.


310
V. Fülöp, M.D., Ph.D., D.Sc., I. Szigetvári, M.D., J. Szepesi, M.D., G. Végh, M.D., M. Singh, M.D., and R. S. Berkowitz, M.D.
The authors developed a national referral center for gestational trophoblastic disease where patient care under the direction of experienced clinicians optimizes the opportunity for cure and minimizes morbidity.


319
S. McGrath, M.D., V. Harding, M.D., A. K. P. Lim, M.D., N. Burfitt, M.D., M. J. Seckl, M.D., Ph.D., and P. Savage, M.D., Ph.D.
Polyvinyl alcohol particle–based radiological uterine artery embolizations are an effective and safe treatment for hemorrhage from arteriovenous vascular malformations in molar pregnancy/gestational trophoblastic tumor patients.


325
M. Kihara, M.D., H. Usui, M.D., H. Tanaka, M.D., H. Inoue, M.D., H. Matsui, M.D., and M. Shozu, M.D.
Complicating preeclampsia correlates significantly with fetal demise but not with subsequent gestational trophoblastic neoplasia in complete hydatidiform mole coexistent with twin fetus.


329
R. Cortés-Charry, M.D., A. Salazar, M.D., V. García-Barriola, M.D., P. Dabed, M.D., L. M. Figueira, M.D., and I. Maestá, M.D.
All cases of hydatidiform mole in ectopic pregnancy were partial mole, with clinical and imaging characteristics similar to those classically described in nonmolar ectopic pregnancy.


333
R. Lertkhachonsuk, M.D., P. Tantbirojn, M.D., and K. Paiwattananupant, M.D.
Immunohistochemistry expression of PTEN and MDM2 show no difference between hydatidiform mole with spontaneous remission and hydatidiform mole with progression to postmolar GTN.


341
M. I. Bianconi, M.D., S. Otero, M.D., O. Moscheni, M.D., L. Alvarez, M.D., C. Storino, M.D., and G. Jankilevich, M.D.
The management of GTD, when adhering to international consensus guidelines, was useful, safe and feasible.


350
C. Alifrangis, M.R.C.P., M. J. Wilkinson, M.B., B.S., D. C. Stefanou, F.R.C.S., J. S. Virk, M.B.B.S., J. Anderson, F.R.C.S, and M. J. Seckl, Ph.D., F.R.C.P.
This case series demonstrates that adjuvant thoracic surgery is an important diagnostic tool in atypical pulmonary presentations of GTN and that in selected cases the resection of pulmonary metastasis can be curative in the context of drug-resistant disease.


359
L. Viçosa Pires, M.D., E. M. Hartmann Uberti, Ph.D., M. do Carmo Fajardo, M.D., A. G. Vieira da Cunha, M.D., M. W. Rosa, M.D., A. C. K. Ayub, M.D., and P. El Beitume, Ph.D.
This cohort study evaluated patients treated at a reference center who underwent hysterectomy for gestational trophoblastic neoplasia.


 

The opinions and statements in this journal are those of the authors and are not attributable to the sponsor, publisher, editors or editorial board of JRM. Product dosages, indications and methods of use referred to in the papers and discussions reflect the authors' clinical experience or are derived from other professional sources.